Gene therapy aims to treat disorders by replacing or introducing genes into cells鈥� either inside the body (in vivo) or outside of the body (ex vivo).
The global market for Cell and Gene Therapy Manufacturing Services was estimated to be worth US$ 4729.8 million in 2023 and is forecast to a readjusted size of US$ 8643.5 million by 2030 with a CAGR of 8.9% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cell and Gene Therapy Manufacturing Services, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cell and Gene Therapy Manufacturing Services by region & country, by Type, and by Application.
The Cell and Gene Therapy Manufacturing Services market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Gene Therapy Manufacturing Services.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific
Merck KGaA
Charles River Laboratories
Lonza
Catalent
WuXi AppTec
Takara Bio Inc
Nikon Corporation
FUJIFILM Holdings Corporation
F. Hoffmann-La Roche
Oxford Biomedica Plc
Cell and Gene Therapy Catapult
The Discovery Labs LLC
RoslinCT
JRS PHARMA
FinVector
ABL
Resilience
BioCentriq
Porton Biopharma Limited
Andelyn Biosciences
Commercializing Living Therapies
Vibalogics
Anemocyte Srl
ElevateBio
Segment by Type:
By Cell Therapy
Allogeneic
Autologous
Viral Vector
By Gene Therapy
Non-viral Vector
Oligonucleotides
Viral Vector
Virus Vector
Segment by Application
Oncology Diseases
Cardiovascular Diseases
Orthopedic Diseases
Ophthalmology Diseases
Infectious Diseases
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cell and Gene Therapy Manufacturing Services manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cell and Gene Therapy Manufacturing Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cell and Gene Therapy Manufacturing Services in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Cell and Gene Therapy Manufacturing Services Product Introduction
1.2 Global Cell and Gene Therapy Manufacturing Services 麻豆原创 Size Forecast
1.3 Cell and Gene Therapy Manufacturing Services 麻豆原创 Trends & Drivers
1.3.1 Cell and Gene Therapy Manufacturing Services Industry Trends
1.3.2 Cell and Gene Therapy Manufacturing Services 麻豆原创 Drivers & Opportunity
1.3.3 Cell and Gene Therapy Manufacturing Services 麻豆原创 Challenges
1.3.4 Cell and Gene Therapy Manufacturing Services 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cell and Gene Therapy Manufacturing Services Players Revenue Ranking (2023)
2.2 Global Cell and Gene Therapy Manufacturing Services Revenue by Company (2019-2024)
2.3 Key Companies Cell and Gene Therapy Manufacturing Services Manufacturing Base Distribution and Headquarters
2.4 Key Companies Cell and Gene Therapy Manufacturing Services Product Offered
2.5 Key Companies Time to Begin Mass Production of Cell and Gene Therapy Manufacturing Services
2.6 Cell and Gene Therapy Manufacturing Services 麻豆原创 Competitive Analysis
2.6.1 Cell and Gene Therapy Manufacturing Services 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Cell and Gene Therapy Manufacturing Services Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Gene Therapy Manufacturing Services as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Allogeneic
3.1.2 Autologous
3.1.3 Viral Vector
3.2 Global Cell and Gene Therapy Manufacturing Services Sales Value by Type
3.2.1 Global Cell and Gene Therapy Manufacturing Services Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cell and Gene Therapy Manufacturing Services Sales Value, by Type (2019-2030)
3.2.3 Global Cell and Gene Therapy Manufacturing Services Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology Diseases
4.1.2 Cardiovascular Diseases
4.1.3 Orthopedic Diseases
4.1.4 Ophthalmology Diseases
4.1.5 Infectious Diseases
4.1.6 Others
4.2 Global Cell and Gene Therapy Manufacturing Services Sales Value by Application
4.2.1 Global Cell and Gene Therapy Manufacturing Services Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cell and Gene Therapy Manufacturing Services Sales Value, by Application (2019-2030)
4.2.3 Global Cell and Gene Therapy Manufacturing Services Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Cell and Gene Therapy Manufacturing Services Sales Value by Region
5.1.1 Global Cell and Gene Therapy Manufacturing Services Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cell and Gene Therapy Manufacturing Services Sales Value by Region (2019-2024)
5.1.3 Global Cell and Gene Therapy Manufacturing Services Sales Value by Region (2025-2030)
5.1.4 Global Cell and Gene Therapy Manufacturing Services Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
5.2.2 North America Cell and Gene Therapy Manufacturing Services Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
5.3.2 Europe Cell and Gene Therapy Manufacturing Services Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
5.4.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
5.5.2 South America Cell and Gene Therapy Manufacturing Services Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
5.6.2 Middle East & Africa Cell and Gene Therapy Manufacturing Services Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cell and Gene Therapy Manufacturing Services Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cell and Gene Therapy Manufacturing Services Sales Value
6.3 United States
6.3.1 United States Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
6.3.2 United States Cell and Gene Therapy Manufacturing Services Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cell and Gene Therapy Manufacturing Services Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
6.4.2 Europe Cell and Gene Therapy Manufacturing Services Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cell and Gene Therapy Manufacturing Services Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
6.5.2 China Cell and Gene Therapy Manufacturing Services Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cell and Gene Therapy Manufacturing Services Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
6.6.2 Japan Cell and Gene Therapy Manufacturing Services Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cell and Gene Therapy Manufacturing Services Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
6.7.2 South Korea Cell and Gene Therapy Manufacturing Services Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cell and Gene Therapy Manufacturing Services Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
6.8.2 Southeast Asia Cell and Gene Therapy Manufacturing Services Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cell and Gene Therapy Manufacturing Services Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cell and Gene Therapy Manufacturing Services Sales Value, 2019-2030
6.9.2 India Cell and Gene Therapy Manufacturing Services Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cell and Gene Therapy Manufacturing Services Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Profile
7.1.2 Thermo Fisher Scientific Main Business
7.1.3 Thermo Fisher Scientific Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.1.4 Thermo Fisher Scientific Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.1.5 Thermo Fisher Scientific Recent Developments
7.2 Merck KGaA
7.2.1 Merck KGaA Profile
7.2.2 Merck KGaA Main Business
7.2.3 Merck KGaA Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.2.4 Merck KGaA Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.2.5 Merck KGaA Recent Developments
7.3 Charles River Laboratories
7.3.1 Charles River Laboratories Profile
7.3.2 Charles River Laboratories Main Business
7.3.3 Charles River Laboratories Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.3.4 Charles River Laboratories Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.3.5 Lonza Recent Developments
7.4 Lonza
7.4.1 Lonza Profile
7.4.2 Lonza Main Business
7.4.3 Lonza Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.4.4 Lonza Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.4.5 Lonza Recent Developments
7.5 Catalent
7.5.1 Catalent Profile
7.5.2 Catalent Main Business
7.5.3 Catalent Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.5.4 Catalent Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.5.5 Catalent Recent Developments
7.6 WuXi AppTec
7.6.1 WuXi AppTec Profile
7.6.2 WuXi AppTec Main Business
7.6.3 WuXi AppTec Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.6.4 WuXi AppTec Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.6.5 WuXi AppTec Recent Developments
7.7 Takara Bio Inc
7.7.1 Takara Bio Inc Profile
7.7.2 Takara Bio Inc Main Business
7.7.3 Takara Bio Inc Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.7.4 Takara Bio Inc Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.7.5 Takara Bio Inc Recent Developments
7.8 Nikon Corporation
7.8.1 Nikon Corporation Profile
7.8.2 Nikon Corporation Main Business
7.8.3 Nikon Corporation Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.8.4 Nikon Corporation Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.8.5 Nikon Corporation Recent Developments
7.9 FUJIFILM Holdings Corporation
7.9.1 FUJIFILM Holdings Corporation Profile
7.9.2 FUJIFILM Holdings Corporation Main Business
7.9.3 FUJIFILM Holdings Corporation Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.9.4 FUJIFILM Holdings Corporation Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.9.5 FUJIFILM Holdings Corporation Recent Developments
7.10 F. Hoffmann-La Roche
7.10.1 F. Hoffmann-La Roche Profile
7.10.2 F. Hoffmann-La Roche Main Business
7.10.3 F. Hoffmann-La Roche Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.10.4 F. Hoffmann-La Roche Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.10.5 F. Hoffmann-La Roche Recent Developments
7.11 Oxford Biomedica Plc
7.11.1 Oxford Biomedica Plc Profile
7.11.2 Oxford Biomedica Plc Main Business
7.11.3 Oxford Biomedica Plc Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.11.4 Oxford Biomedica Plc Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.11.5 Oxford Biomedica Plc Recent Developments
7.12 Cell and Gene Therapy Catapult
7.12.1 Cell and Gene Therapy Catapult Profile
7.12.2 Cell and Gene Therapy Catapult Main Business
7.12.3 Cell and Gene Therapy Catapult Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.12.4 Cell and Gene Therapy Catapult Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.12.5 Cell and Gene Therapy Catapult Recent Developments
7.13 The Discovery Labs LLC
7.13.1 The Discovery Labs LLC Profile
7.13.2 The Discovery Labs LLC Main Business
7.13.3 The Discovery Labs LLC Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.13.4 The Discovery Labs LLC Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.13.5 The Discovery Labs LLC Recent Developments
7.14 RoslinCT
7.14.1 RoslinCT Profile
7.14.2 RoslinCT Main Business
7.14.3 RoslinCT Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.14.4 RoslinCT Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.14.5 RoslinCT Recent Developments
7.15 JRS PHARMA
7.15.1 JRS PHARMA Profile
7.15.2 JRS PHARMA Main Business
7.15.3 JRS PHARMA Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.15.4 JRS PHARMA Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.15.5 JRS PHARMA Recent Developments
7.16 FinVector
7.16.1 FinVector Profile
7.16.2 FinVector Main Business
7.16.3 FinVector Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.16.4 FinVector Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.16.5 FinVector Recent Developments
7.17 ABL
7.17.1 ABL Profile
7.17.2 ABL Main Business
7.17.3 ABL Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.17.4 ABL Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.17.5 ABL Recent Developments
7.18 Resilience
7.18.1 Resilience Profile
7.18.2 Resilience Main Business
7.18.3 Resilience Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.18.4 Resilience Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.18.5 Resilience Recent Developments
7.19 BioCentriq
7.19.1 BioCentriq Profile
7.19.2 BioCentriq Main Business
7.19.3 BioCentriq Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.19.4 BioCentriq Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.19.5 BioCentriq Recent Developments
7.20 Porton Biopharma Limited
7.20.1 Porton Biopharma Limited Profile
7.20.2 Porton Biopharma Limited Main Business
7.20.3 Porton Biopharma Limited Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.20.4 Porton Biopharma Limited Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.20.5 Porton Biopharma Limited Recent Developments
7.21 Andelyn Biosciences
7.21.1 Andelyn Biosciences Profile
7.21.2 Andelyn Biosciences Main Business
7.21.3 Andelyn Biosciences Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.21.4 Andelyn Biosciences Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.21.5 Andelyn Biosciences Recent Developments
7.22 Commercializing Living Therapies
7.22.1 Commercializing Living Therapies Profile
7.22.2 Commercializing Living Therapies Main Business
7.22.3 Commercializing Living Therapies Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.22.4 Commercializing Living Therapies Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.22.5 Commercializing Living Therapies Recent Developments
7.23 Vibalogics
7.23.1 Vibalogics Profile
7.23.2 Vibalogics Main Business
7.23.3 Vibalogics Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.23.4 Vibalogics Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.23.5 Vibalogics Recent Developments
7.24 Anemocyte Srl
7.24.1 Anemocyte Srl Profile
7.24.2 Anemocyte Srl Main Business
7.24.3 Anemocyte Srl Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.24.4 Anemocyte Srl Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.24.5 Anemocyte Srl Recent Developments
7.25 ElevateBio
7.25.1 ElevateBio Profile
7.25.2 ElevateBio Main Business
7.25.3 ElevateBio Cell and Gene Therapy Manufacturing Services Products, Services and Solutions
7.25.4 ElevateBio Cell and Gene Therapy Manufacturing Services Revenue (US$ Million) & (2019-2024)
7.25.5 ElevateBio Recent Developments
8 Industry Chain Analysis
8.1 Cell and Gene Therapy Manufacturing Services Industrial Chain
8.2 Cell and Gene Therapy Manufacturing Services Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cell and Gene Therapy Manufacturing Services Sales Model
8.5.2 Sales Channel
8.5.3 Cell and Gene Therapy Manufacturing Services Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Thermo Fisher Scientific
Merck KGaA
Charles River Laboratories
Lonza
Catalent
WuXi AppTec
Takara Bio Inc
Nikon Corporation
FUJIFILM Holdings Corporation
F. Hoffmann-La Roche
Oxford Biomedica Plc
Cell and Gene Therapy Catapult
The Discovery Labs LLC
RoslinCT
JRS PHARMA
FinVector
ABL
Resilience
BioCentriq
Porton Biopharma Limited
Andelyn Biosciences
Commercializing Living Therapies
Vibalogics
Anemocyte Srl
ElevateBio
听
听
*If Applicable.
